◆ NeutralEPRX
Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders
GlobeNewswire Inc.·
Eupraxia Pharmaceuticals held its Annual General Meeting on June 18, 2026, where all seven board nominees were elected with strong shareholder support. The company also re-appointed KPMG LLP as auditor. Eupraxia is a clinical-stage biotech company developing locally delivered, extended-release products using its proprietary Diffusphere™ technology, with current programs in pain management and inflammatory gastrointestinal disease.
Read Full Article at GlobeNewswire Inc. →